Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Aims: Muscle strengthening exercises are one of the interventions frequently prescribed by physiotherapists for adolescents with cerebral palsy (CP). However, there is wide variability in the exercise regimes used and limited evidence of their effectiveness. The ROBUST trial will assess the clinical effectiveness of an individually tailored strengthening programme, including progressive resistance exercises and advice, compared to usual care for ambulant adolescents with spastic CP.

Methods: We are conducting a multicentre, two-arm, parallel group, superiority randomized controlled trial. We will recruit adolescents aged 12 to 18 years with a diagnosis of spastic CP (bilateral or unilateral) Gross Motor Function Classification System (GMFCS) levels I to III who are able to comply with the assessment procedures and exercise programme with or without support. Participants will be recruited from at least 12 UK NHS Trust physiotherapy and related services. Participants (n = 334) will be randomized (centralized computer-generated 1:1 allocation ratio) to either: 1) a progressive resistance exercise programme, with six one-to-one physiotherapy sessions over 16 weeks; or 2) usual NHS care, with a single physiotherapy session and an assessment session, and advice regarding self-management and exercise.

Conclusion: The primary outcome is functional mobility measured using the child-/parent-reported Gait Outcomes Assessment List (GOAL) at six months. Secondary outcomes are: clinician-assessed muscle strength (Five Times Sit-to-Stand Test) and motor function (timed up and go test) at six months; functional mobility (GOAL) at 12 months; independence (GOAL subdomain A), balance (GOAL subdomain A, B, D), pain and discomfort (GOAL subdomain C), health-related quality of life (youth version of the EuroQol five-dimension questionnaire; EQ-5D-Y), educational attendance, exercise adherence, and additional physiotherapy treatment (six and 12 months). The primary analysis will be intention to treat.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12043368PMC
http://dx.doi.org/10.1302/2633-1462.65.BJO-2024-0268DOI Listing

Publication Analysis

Top Keywords

progressive resistance
12
goal subdomain
12
clinical effectiveness
8
effectiveness individually
8
individually tailored
8
tailored strengthening
8
strengthening programme
8
programme including
8
including progressive
8
resistance exercises
8

Similar Publications

Phage therapy in finfish aquaculture: how to get there?

Trends Microbiol

September 2025

Marine Biological Section, Department of Biology, University of Copenhagen, Helsingør, Denmark; HADAL & Nordcee, Department of Biology, University of Southern Denmark, Odense, Denmark. Electronic address:

As antimicrobial resistance threatens the future of the aquaculture industry, numerous studies have investigated the use of phages against aquaculture diseases over the past decades. Despite reports of efficient pathogen control, commercial phage solutions are sparse. We discuss limitations of phage therapy and provide suggestions for the progression towards commercially viable solutions.

View Article and Find Full Text PDF

[Research status and future direction of irreversible EGFR-TKI in non-small cell lung cancer].

Zhonghua Jie He He Hu Xi Za Zhi

September 2025

Department of nursing, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510000, China.

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are important treatments for EGFR mutant non-small cell lung cancer (NSCLC). However, the first and second generation EGFR-TKI face clinical limitations due to acquired resistance, such as the T790M mutation. Irreversible EGFR-TKI can significantly prolong the survival of patients by enhancing the inhibition of drug-resistant mutations through the covalent binding mechanism.

View Article and Find Full Text PDF

Background: Antimicrobial resistance (AMR) transmission is shaped by a complex interplay of health system factors, many of which remain underexplored or insufficiently addressed. This study investigates concrete systemic transmission drivers in hospitals and long-term care facilities (LTCFs) for older adults in Merseyside, UK.

Methods: Qualitative data were collected through semi-structured interviews with 37 purposively selected participants across hospitals, LTCFs, community settings, and ambulance services.

View Article and Find Full Text PDF

Sequential YAP-1/FOSL-1 silencing and epigenetic therapy to overcome stromal barriers in pancreatic cancer.

Int J Pharm

September 2025

CINBIO, Immunology Group, Universidade de Vigo 36310 Vigo, Spain; Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain. Electronic address:

Pancreatic ductal adenocarcinoma (PDAC) remains a highly aggressive malignancy with poor therapeutic outcomes due to its desmoplastic tumor microenvironment (TME), hindering drug and activated immune cell penetration. Cancer-associated fibroblasts (CAFs) are central in supporting tumor growth and forming a protective stroma. We propose a novel dual-therapy targeting the Hippo pathway and histone deacetylation, both involved in tumor progression, resistance, and stromal interactions, to overcome PDAC therapeutic resistance.

View Article and Find Full Text PDF

Renal cell carcinoma (RCC) is a heterogeneous kidney malignancy driven by complex genetic, molecular, and metabolic alterations. Emerging evidence implicates centrosome dysfunction and autophagy dysregulation in RCC initiation, progression, and resistance to therapy. The centrosome plays a critical role in mitotic fidelity, and its dysfunction often leads to chromosomal and genomic instability.

View Article and Find Full Text PDF